PMID: 2102085Dec 1, 1990Paper

Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins

Atherosclerosis
E NakandakareE C Quintão

Abstract

Simvastatin, 10-40 mg/d (n = 11), bezafibrate, 600 mg/d (n = 6), and gemfibrozil, 1200 mg/d (n = 5) were administered for 12 weeks after a 4-week placebo period to subjects with initial plasma levels (mg/100 ml. mean +/- SD) of cholesterol (346 +/- 77), and of triglycerides (180 +/- 54). Total LDL-C plasma concentration was lowered 32% by simvastatin and 35% by bezafibrate, but only bezafibrate diminished the triglyceride (41%) and increased HDL-C plasma levels (35%). Plasma lipoprotein fractions obtained by discontinuous gradient ultracentrifugation, namely, VLDL, lighter LDL (LDL-1), heavier LDL (LDL-2) and bulk HDL were chemically analyzed. Simvastatin and bezafibrate significantly diminished the quantity of VLDL and LDL-1 particles, although barely modifying their composition. Neither drug influenced the LDL-2 plasma concentration. Bezafibrate increased the total plasma HDL level little interfering with its chemical composition. Gemfibrozil was the least effective of all drugs but decreased the lipid and protein contents and their ratios in VLDL and LDL-2.

References

May 12, 1975·Analytical Biochemistry·T G RedgraveC E West
Jul 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J C GibsonH C Seftel
Jul 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·T A MuslinerR M Krauss
May 24, 1983·Biochimica Et Biophysica Acta·R W Mahley, T L Innerarity
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S M Grundy, D W Bilheimer
Dec 1, 1984·The Journal of Clinical Investigation·J ShepherdH G Morgan
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein

❮ Previous
Next ❯

Citations

Jun 16, 2006·Cardiovascular Drugs and Therapy·Manfredi Rizzo, Kaspar Berneis
Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Sep 30, 1994·Atherosclerosis·P M CliftonP J Nestel
Apr 1, 1997·Journal of the American College of Nutrition·I GirouxH Jacques
May 24, 2007·Current Medical Research and Opinion·Manfredi Rizzo, Kaspar Berneis
Jun 6, 1994·The American Journal of Medicine·H GretenH Eskötter
Dec 24, 2005·QJM : Monthly Journal of the Association of Physicians·M Rizzo, K Berneis

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.